Pfizer (PFE)
(Delayed Data from NYSE)
$24.65 USD
+0.36 (1.48%)
Updated Oct 31, 2025 04:00 PM ET
After-Market: $24.67 +0.02 (0.08%) 7:58 PM ET
4-Sell of 5 4
B Value F Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PFE 24.65 +0.36(1.48%)
Will PFE be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for PFE based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for PFE
Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy?
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View
What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
Other News for PFE
Earnings Scorecard: 24 out of 25 healthcare firms deliver EPS wins this week
Trending stocks this week: Wall Street extends rally on Big Tech earnings, trade optimism, Fed rate cut
Dividend Champion, Contender, And Challenger Highlights: Week Of November 2
What You Missed On Wall Street On Friday
Palantir, Qualcomm Set To Report Earnings